Prostaglandin D Synthase (lipocalin-type, human recombinant)

Prostaglandin D synthase (PGDS) catalyzes the isomerization of PGH2 to produce PGD2. PGD2 induces sleep, regulates nociception, inhibits platelet aggregation, and acts as an allergic mediator. Two distinct types of PGDS have been identified, namely the lipocalin-type enzyme and the hematopoietic enzyme. L-PGDS is localized in the central nervous system and male genital organs of various mammals and the human heart. This enzyme has been identified as beta-trace, which is a major protein in human cerebrospinal fluid. Cayman's L-PGDS (human recombinant) is a highly-purified GST-fusion protein isolated from an E. coli expression system. Cysteines 89 and 186 have been changed to alanines to prevent protein misfolding.Synonyms: Lipocalin-PGDS, L-PGDS. Purity: >85% estimated by SDS-PAGE. Source: Recombinant N-terminal GST-tagged enzyme purified from E. coli. MW: 46 kDa/subunit. Formulation: (Request formulation change), 50 mM sodium phosphate, pH 7.2, containing 20% glycerol, 150 mM sodium chloride, 1 mM DTT, and 0.5 mM EDTA. UniProt Accession #: P41222.